دورية أكاديمية
Transcatheter aortic valve implantation versus surgical aortic valve replacement in severe aortic stenosis patients at low surgical mortality risk: a cost-effectiveness analysis in Belgium.
| العنوان: | Transcatheter aortic valve implantation versus surgical aortic valve replacement in severe aortic stenosis patients at low surgical mortality risk: a cost-effectiveness analysis in Belgium. |
|---|---|
| المؤلفون: | Dubois, Christophe, Adriaenssens, Tom, Annemans, Lieven, Bosmans, Johan, Callebaut, Britt, Candolfi, Pascal, Cornelis, Kristoff, Delbaere, Alexis, Green, Michelle, Kefer, Joelle, Lancellotti, Patrizio, Rosseel, Michael, Shore, Judith, Van Der Heyden, Jan, Vermeersch, Sebastian, Wyffels, Eric |
| المصدر: | Acta Cardiologica, 79 (1), 46-57 (2024-02) |
| بيانات النشر: | Taylor & Francis, 2024. |
| سنة النشر: | 2024 |
| مصطلحات موضوعية: | Humans, Aortic Valve/surgery, Transcatheter Aortic Valve Replacement, Cost-Effectiveness Analysis, Belgium/epidemiology, Quality of Life, Constriction, Pathologic, Aortic Valve Stenosis/surgery, SAVR, TAVI, aortic stenosis, cost-effectiveness, low risk, Human health sciences, Cardiovascular & respiratory systems, Sciences de la santé humaine, Systèmes cardiovasculaire & respiratoire |
| الوصف: | BACKGROUND: Transcatheter aortic valve implantation (TAVI) with the SAPIEN 3 device has recently shown significant clinical benefits, compared to surgical aortic valve replacement (SAVR), in patients at low risk for surgical mortality (PARTNER 3 trial, NCT02675114). Currently in Belgium, TAVI use is restricted to high-risk or inoperable patients with severe symptomatic aortic stenosis (sSAS). This cost-utility analysis aimed to assess whether TAVI with SAPIEN 3 could lead to potential cost-savings compared with SAVR, in the low-risk sSAS population in Belgium. METHODS: A previously published, two-stage, Markov-based cost-utility model was used. Clinical outcomes were captured using data from PARTNER 3 and the model was adapted for the Belgian context using cost data from the perspective of the Belgian National Healthcare System, indexed to 2022. A lifetime horizon was chosen. The model outputs included changes in direct healthcare costs, survival and health-related quality of life using TAVI versus SAVR. RESULTS: TAVI with SAPIEN 3 provides meaningful clinical and cost benefits over SAVR, in terms of an increase in quality-adjusted life years (QALYs) of 0.94 and cost-saving of €3 013 per patient. While initial procedure costs were higher for TAVI compared with SAVR, costs related to rehabilitation, disabling stroke, treated atrial fibrillation, and rehospitalization were lower. The cost-effectiveness of TAVI over SAVR remained robust in sensitivity analyses. CONCLUSION: TAVI with SAPIEN 3 may offer a meaningful alternative intervention to SAVR in Belgian low-risk patients with sSAS, showing both clinical benefits and cost savings associated with post-procedure patient management. |
| نوع الوثيقة: | journal article http://purl.org/coar/resource_type/c_6501Test article peer reviewed |
| اللغة: | English |
| العلاقة: | urn:issn:0001-5385; urn:issn:1784-973X |
| DOI: | 10.1080/00015385.2023.2282283 |
| الوصول الحر: | https://orbi.uliege.be/handle/2268/314105Test |
| حقوق: | open access http://purl.org/coar/access_right/c_abf2Test info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsorb.314105 |
| قاعدة البيانات: | ORBi |
| DOI: | 10.1080/00015385.2023.2282283 |
|---|